Skip to main content
. 2022 Jan 17;37(4):713–723. doi: 10.1002/mds.28913

TABLE 2.

Demographic and clinical characteristics of the study participants

HC (n = 10) a PD‐NC (n = 40) PD‐MCI (n = 17) P‐value
Age (y) 54.6 (6.0) 63.4 (7.4) 67.5 (9.6) <0.001 * , b
Gender, male n (% male) 5 (50%) 19 (47.5%) 13 (76.5%) 0.124
Educational level c 5.0 (1.0) 5.0 (2.0) 6.0 (1.0) 0.704
Motor symptom duration (mo) 20.2 (11.8) 25.1 (17.2) 0.273
MDS‐UPDRS‐III, total score 28.2 (9.1) 36.8 (14.1) 0.008 *
Motor phenotype, n TD/PIGD/indeterminate 15/18/7 4/12/1 0.189
Hoehn and Yahr stage d 2.0 (1.0); 26.7 2.0 (1.0); 34.5 0.050
MoCA, total score 28.4 (0.8) 26.1 (2.6) 23.7 (3.2) <0.001 * , e
HADS anxiety, total score 4.5 (2.6) 4.7 (2.4) 0.778
HADS depression, total score 3.4 (2.4) 4.6 (2.6) 0.085
*

Statistically significant (p < 0.05)

a

Data are presented as mean (standard deviation) unless otherwise indicated.

b

Post hoc analysis: HC < PD‐NC; HC < PD‐MCI.

c

Educational level according to the Dutch Verhage scale (Verhage, 1964), listed as median (interquartile range).

d

Hoehn and Yahr stage is listed as median (interquartile range); mean rank.

e

Post hoc analysis: HC > PD‐NC > PD‐MCI.

Abbreviations: HC, healthy control; PD‐NC, Parkinson's disease normal cognition; PD‐MCI, Parkinson's disease mild cognitive impairment; MDS‐UPDRS‐III, Movement Disorder Society‐Revised Unified Parkinson's Disease Rating Scale, Part III; TD, tremor dominant; PIGD, postural instability and gait difficulty; MoCA, Montreal Cognitive Assessment; HADS, Hospital Anxiety and Depression Scale.